Literature DB >> 19653937

Concentration-time profiles of gamma-hydroxybutyrate in blood after recreational doses are best described by zero-order rather than first-order kinetics.

A W Jones1, A Eklund, R Kronstrand.   

Abstract

The recreational drug gamma-hydroxybutyrate (GHB) has a short plasma elimination half-life (t(1/2)) reported to be about 30-50 min. However, this represents a terminal half-life and therefore might not necessarily apply after large (abuse) doses are taken. Clinical studies with sodium oxybate (sodium salt of GHB) suggest that zero-order rather than first-order kinetics are more appropriate to describe post-peak concentration-time (C-T) profiles. We report the case of a 23-year-old male found unconscious by the police and a blood sample contained 100 mg/L GHB and 0.14 g% ethanol. On regaining consciousness the man admitted drinking alcohol about 6 h earlier but claimed that his drink must have been spiked with GHB. The police wanted to know how much GHB had been administered to account for the man's clinical condition. A back-calculation for 6 h, assuming a GHB half-life of 40 min, gives a very high concentration in blood of approximately 900 mg/L, which would probably have proven fatal. Back-calculating using zero-order kinetics and a proposed elimination rate of 18 mg/L per hour leads to a GHB concentration of 208 mg/L, which is much more realistic. Toxicologists should not arbitrarily apply the principles of first-order kinetics after abuse doses of drugs, when zero-order or saturation kinetics (Michaelis-Menten) are more appropriate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19653937     DOI: 10.1093/jat/33.6.332

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  6 in total

Review 1.  Illicit substance use in pregnancy - a review.

Authors:  Katherine Scott; Karin Lust
Journal:  Obstet Med       Date:  2010-09-17

2.  The Population Pharmacokinetics of D-β-hydroxybutyrate Following Administration of (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate.

Authors:  Vittal Shivva; Pete J Cox; Kieran Clarke; Richard L Veech; Ian G Tucker; Stephen B Duffull
Journal:  AAPS J       Date:  2016-02-18       Impact factor: 4.009

3.  Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway.

Authors:  Muhammad S Al-Samarraie; Ritva Karinen; Jørg Mørland; Mimi Stokke Opdal
Journal:  Eur J Clin Pharmacol       Date:  2010-08-18       Impact factor: 2.953

4.  Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects.

Authors:  Matthias E Liechti; Boris B Quednow; Evangelia Liakoni; Dario Dornbierer; Robin von Rotz; Maria Salomé Gachet; Jürg Gertsch; Erich Seifritz; Oliver G Bosch
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

Review 5.  GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.

Authors:  Francesco P Busardò; Alan W Jones
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

6.  Presentations to an urban emergency department in Switzerland due to acute γ-hydroxybutyrate toxicity.

Authors:  Evangelia Liakoni; Fabio Walther; Christian H Nickel; Matthias E Liechti
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2016-08-31       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.